Alzheimer Disease Clinical Trial
Official title:
A Scalable Mediterranean-ketogenic Nutrition Intervention to Improve Gut and Brain Health in Underserved Rural Older Adults With Mild Cognitive Impairment
Objective 1: To scale-up the nutrition adherence intervention for testing in predominantly Black and African-American rural communities in North Florida. The investigators hypothesize that: 1. The protocol will produce at least 75% of participants obtaining measurable levels of urine ketones (e.g., good adherence) in the Mediterranean-Ketogenic nutrition (MKN) group and an average score of >9 on the MEDAS questionnaire in the Mediterranean group during the 10-week program. Objective 2: To evaluate the effects of adherence to Mediterranean versus Mediterranean-Ketogenic nutrition on novel gut-brain axis markers of Alzheimer's disease pathogenesis in individuals with mild cognitive impairment compared to cognitively normal older adults. The investigators hypothesize that individuals with mild cognitive impairment will: 1. Have greater evidence of gut dysbiosis at baseline than cognitively normal controls and 2. Will demonstrate greater increases in beneficial gut microbial metabolites in response to adherence to Mediterranean-Ketogenic nutrition and the Mediterranean diet compared to CN controls.
Status | Recruiting |
Enrollment | 64 |
Est. completion date | January 2027 |
Est. primary completion date | January 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 55 Years to 85 Years |
Eligibility | Inclusion Criteria: - Ages 55-85 - converted telephone MoCA total score: MCI = 17 = 26, CN= =27 and/or and/or MCS MCI=3, CN<3 - interest in participating in a nutrition program - stable medical condition (at least 3 months prior to screening visit) at the discretion of study physician - stable on medications if any (at least 4 weeks prior to screening visit) at the discretion of study physician - able to complete the required assessments Exclusion Criteria: - MoCA = 16, or diagnosis of neurodegenerative illness (except MCI or early AD in the MCI group) - current evidence or history in the last 1 year of focal brain lesion, head injury with loss of consciousness, or any major psychiatric disorder including psychosis, bipolar disorder, severe major depression (PHQ-9 > 20), alcohol or substance abuse, or disordered eating symptoms (SCOFF > 2) - sensory impairment (visual or auditory) that might preclude participant from participating in the study - serious medical risk or organ failure, such as type 1 diabetes mellitus, recent cardiac event (e.g. heart attack, angioplasty) - prescribed Warfarin, insulin, or immunosuppressants - use of medications including anticonvulsants, drugs with potential interfering CNS effects (except cholinesterase inhibitors or memantine), and medications with known anticholinergic activity - a nut or fish allergy (does not include shellfish) - current use of highly restrictive or specialized diet regimen (e.g., vegan, use of MAOIs etc.) - major digestive disorders, absorption issues, or surgeries that could be exacerbated by dietary intervention - Non-English speaking. |
Country | Name | City | State |
---|---|---|---|
United States | 2010 Levy Ave - Center for Translational Behavioral Science | Tallahassee | Florida |
Lead Sponsor | Collaborator |
---|---|
Florida State University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Total cholesterol | A commercially available analyzer will be used to assess changes in cholesterol level. | Baseline, 10-weeks, 6 months, 12 months | |
Other | Sleep | The Pittsburgh Sleep Quality Index (PSQI). Scores for each question range from 0 to 3, with higher scores indicating more acute sleep disturbances. | Baseline, 10-weeks, 6 months, 12 months | |
Other | Blood glucose levels | A commercially available analyzer will be used to assess changes in blood glucose levels. | Baseline, 10-weeks, 6 months, 12 months | |
Other | Mood | Patient Health Questionnaire (PHQ-9). Total scores of 5, 10, 15, and 20 represent cut off points for mild, moderate, moderately severe and severe depression. | Baseline, 10-weeks, 6 months, 12 months | |
Other | Pain and Pain-related disability | Roland-Morris Pain and Pain-related Disability Questionnaire (RMQ).Total RMQ scores range from 0 to 24; higher scores represent higher levels of pain-related disability. | Baseline, 10-weeks, 6 months, 12 months | |
Other | Physical Activity | Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire, examining frequency and duration as primary outcomes. Scores are of moderate or greater activity if MET values > 3.0. | Baseline, 10-weeks, 6 months, 12 months | |
Primary | Ketosis (adherence) | Participants will show measurable levels of ketones using at-home urinalysis test strips by week 10 of the intervention, as evidenced by small trace amounts of ketones on the urine strips. | Baseline, 10-weeks, 6 months, 12 months | |
Primary | Mediterranean Diet (adherence) | Participants will show acceptable adherence to a Mediterranean diet by week 10 of the intervention, as shown by an average score of >9 on Mediterranean Diet Adherence Screener (MEDAS) questionnaire. | Baseline, 10-weeks, 6 months, 12 months | |
Primary | Gut Microbial Metabolites | Participants with MCI will show greater increases in beneficial gut microbial metabolites in response to M-KN and the Mediterranean diet compared to CN controls demonstrating beneficial changes in the gut brain axis. | Baseline, 10-weeks, 6 months, 12 months | |
Secondary | Clinical signal of effect | Clinical change on the total scaled score of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) from baseline to 12-month follow up, with higher scores indicating greater improvement in cognitive functioning at follow up. | Baseline, 10-weeks, 6 months, 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |